This Article Full Text Full Text (PDF) All Versions of this Article: 200209-998OCv1 167/6/824    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Stout, J. E. Articles by Hamilton, C. D. Search for Related Content PubMed PubMed Citation Articles by Stout, J. E. Articles by Hamilton, C. D.

Safety of 2 Months of Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis

Division of Infectious Diseases, Duke University Medical Center, Durham, and Wake County Human Services, Raleigh, North Carolina

Correspondence and requests for reprints should be addressed to Jason E. Stout, Box 3306, Duke University Medical Center, Durham, NC 27710. E-mail: stout002{at}mc.duke.edu

An alternative regimen for the treatment of latent tuberculosis infection is 2 months of rifampin and pyrazinamide, but some patients have died of hepatitis associated with this therapy. One hundred fourteen patients received rifampin/pyrazinamide in Wake County, North Carolina, between December 1999 and May 2002; 60.5% of these patients were homeless, and at least 17% drank alcohol to excess. Seventy-seven patients (67.5%) completed a full 2-month course. Nine patients had a history of viral hepatitis or chronic liver disease. Four of 114 (3.5%; 95% confidence interval, 1.0–8.7%) patients developed hepatitis on therapy, and another two had symptoms consistent with hepatitis but did not report for laboratory testing (total confirmed plus suspected hepatitis rate 5.3%; 95% confidence interval, 2.0–11.1%). No patient who developed hepatitis had a history of viral hepatitis or liver disease, and none had been previously treated with isoniazid. No patients died or were hospitalized due to drug side effects. Rifampin/pyrazinamide was associated with a significantly higher rate of hepatitis than previously described with isoniazid therapy for latent tuberculosis but resulted in a high completion rate. The rifampin/pyrazinamide regimen for latent tuberculosis infection may be useful for high-risk, traditionally nonadherent patient groups, but careful monitoring for toxicity is required.

Key Words: tuberculosis • hepatitis • side effects

This article has been cited by other articles:

				J. J. Saukkonen, D. L. Cohn, R. M. Jasmer, S. Schenker, J. A. Jereb, C. M. Nolan, C. A. Peloquin, F. M. Gordin, D. Nunes, D. B. Strader, et al. An Official ATS Statement: Hepatotoxicity of Antituberculosis Therapy. Am. J. Respir. Crit. Care Med., October 15, 2006; 174(8): 935 - 952. [Abstract] [Full Text] [PDF]

				M. Schechter, R. Zajdenverg, G. Falco, G. L. Barnes, J. C. Faulhaber, J. S. Coberly, R. D. Moore, and R. E. Chaisson Weekly Rifapentine/Isoniazid or Daily Rifampin/Pyrazinamide for Latent Tuberculosis in Household Contacts Am. J. Respir. Crit. Care Med., April 15, 2006; 173(8): 922 - 926. [Abstract] [Full Text] [PDF]

				British Thoracic Society Standards of Care Committ BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-{alpha} treatment Thorax, October 1, 2005; 60(10): 800 - 805. [Abstract] [Full Text] [PDF]

				A. B. Younossian, T. Rochat, J-P. Ketterer, J. Wacker, and J-P. Janssens High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis Eur. Respir. J., September 1, 2005; 26(3): 462 - 464. [Abstract] [Full Text] [PDF]

				M. N. Lobato, R. R. Reves, R. M. Jasmer, J. C. Grabau, N. N. Bock, N. Shang, and for the 2RZ Study Group Adverse Events and Treatment Completion for Latent Tuberculosis in Jail Inmates and Homeless Persons Chest, April 1, 2005; 127(4): 1296 - 1303. [Abstract] [Full Text] [PDF]

				D. Menzies, M.-J. Dion, B. Rabinovitch, S. Mannix, P. Brassard, and K. Schwartzman Treatment Completion and Costs of a Randomized Trial of Rifampin for 4 Months versus Isoniazid for 9 Months Am. J. Respir. Crit. Care Med., August 15, 2004; 170(4): 445 - 449. [Abstract] [Full Text] [PDF]

				M. J. Tobin Tuberculosis, Lung Infections, Interstitial Lung Disease, Social Issues and Journalology in AJRCCM 2003 Am. J. Respir. Crit. Care Med., January 15, 2004; 169(2): 288 - 300. [Full Text] [PDF]

				C. C. Leung, W. S. Law, K. C. Chang, C. M. Tam, W. W. Yew, C. K. Chan, and M. Y. Wong Initial Experience on Rifampin and Pyrazinamide vs Isoniazid in the Treatment of Latent Tuberculosis Infection Among Patients With Silicosis in Hong Kong Chest, December 1, 2003; 124(6): 2112 - 2118. [Abstract] [Full Text] [PDF]

				P. A. LoBue and K. S. Moser Use of Isoniazid for Latent Tuberculosis Infection in a Public Health Clinic Am. J. Respir. Crit. Care Med., August 15, 2003; 168(4): 443 - 447. [Abstract] [Full Text] [PDF]

				Two Months of RIF/PZA: Safe? Journal Watch Infectious Diseases, April 11, 2003; 2003(411): 4 - 4. [Full Text]

				R. M. Jasmer and C. L. Daley Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis Infection: Is It Safe? Am. J. Respir. Crit. Care Med., March 15, 2003; 167(6): 809 - 810. [Full Text] [PDF]